KLRK1 and hepatocellular carcinoma: The findings highlight the targeted eradication of HCC cells by NKG2D-BBz CAR-T cells in an NKG2DL-dependent manner, laying the groundwork for advancing towards clinical trials involving NKG2DL-positive patients (73).